Please ensure Javascript is enabled for purposes of website accessibility

Diabetes Partners Going Their Separate Ways

By Brian Orelli, PhD - Dec 19, 2013 at 7:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bristol-Myers Squibb sells its part of the diabetes JV to AstraZeneca. The big loser could be MannKind, with one less potential partner.

"It's not you; it's me."

That's basically what Bristol-Myers Squibb (BMY -1.87%) said to AstraZeneca (AZN 1.05%) as it ended their nearly seven-year marriage in diabetes.

In addition to developing drugs as part of the joint venture, the two companies bought an entire company, Amylin Pharmaceuticals, together. Apparently keeping the union together for the kids wasn't an option. The companies seem to have different priorities.

Given the choice, Bristol-Myers would rather sell a billion-dollar cancer drug than a billion-dollar diabetes drug because the margins are much higher with the cancer drug.

AstraZeneca is already heavily focused on primary-care doctors with drugs like its cholesterol drug Crestor. Economies of scale make the lower margins more tolerable.

The deal
AstraZeneca will pay Bristol-Myers $2.7 billion upfront for the full rights to the joint venture, and there's potential for another quick $700 million if AstraZeneca gets regulatory approvals for Forxiga in the first quarter of next year. Bristol-Myers is eligible for another $700 million in undisclosed regulatory- and sales-based milestone payments and royalties on sales through 2015. There's also $225 million for additional assets that may be subsequently transferred to AstraZeneca.

Bristol-Myers' share of the cost to purchase Amylin was a little more than $3 billion, so the company is essentially just getting its money back. The good news is the cash influx will be tax free. The bad news is that it's counting on AstraZeneca's ability to sell the drugs to get those royalties and sales milestones. While that's not as ideal as having control of your own destiny, at least Bristol-Myers has inside knowledge of how AstraZeneca operates.

There goes my prediction?
I've previously pointed out that the Bristol-Myers-Squibb-AstraZeneca diabetes partnership would be a good fit for MannKind's (MNKD -2.85%) inhaled insulin Afreza. The market for the drug is uncertain because there hasn't been anything like it before, and sharing that risk among two pharmas made a lot of sense. Now, not only would AstraZeneca have to take on all the risk, but I doubt it would want to add a drug while it was in the transition of taking full control of the joint venture.

There are certainly other possible large pharma partners that MannKind could team up with; Eli Lilly (LLY 3.20%) and Boehringer Ingelheim have a diabetes joint venture, although it's hard to see Eli Lilly jumping into inhaled insulin after dropping its own program. But clearly today's deal is a net negative for MannKind assuming it has one less potential partner to do a deal with.

Let the predictions begin
Bristol-Myers won't sit on the cash it's getting from AstraZeneca. Dividends and share repurchases were mentioned on the conference call today, but the pharma has been very active with its "string of pearls" strategy of adding drugs through acquisitions. With a more focused specialty pharma, more additions seem like a foregone conclusion.

Who do you think Bristol-Myers could target? Sound off in the comment box below.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$76.14 (-1.87%) $-1.45
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$67.40 (1.05%) $0.70
MannKind Corporation Stock Quote
MannKind Corporation
$4.44 (-2.85%) $0.13
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$323.48 (3.20%) $10.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.